Para-aortic lymph node (No.16) metastasis has been accepted as a factor responsible for non-curability in gastric cancer surgery. Recently in Key words: gastric cancer•\para-aortic node•\vena cava•\abdominal aorta•\lymph flow•\prognosis
Japan, after detailed experimental
and clinical studies of the lymph flows from the stomach and/or perigastric nodes to these No. 16 nodes, it is now considered to be curable.
From 5 autopsy cases, the mean number of No. 16 nodes has been determined to be 43. The frequency of positive No. 16 metas tasis (No. 16 (+) ) was found to be 24%, occurring in 35 of 144 cases with ad vanced gastric cancer following R3 gastrectomy plus No. 16 dissection.
The 5 year-survival rate of R3+No. 16 dissection was 70.1% in ni (+), 49.8% in n2 (+) and 24.3% in n3 (+) and had better prognoses (by Kaplan-Meier sta tistics) than those without dissection of the Number of para-aortic lymph node (No. 16) dissections and the metastatic rate [1984] [1985] [1986] [1987] [1988] [1989] Among the 144 cases of R3+No. 16 dis section, No. 16 node metastasis was found in 35 (24%) cases (Table 2 ). Fig. 2 shows intraoperative views of one case following total R3 gastrectomy with No. 16 dissection.
In this case, 52 of 58 No. 16 nodes had pathological me tastases.
However, the patient survived 2 years and 3 months, postoperatively, without chemotherapy and enjoyed a good quality of life (Table 3) .
The 5 year-survival rates with and without No. 16 dissection are summarized in Effects of para-aortic lymph node dissection on the cumulative 5 year-survival rate Kaplan-Meier (1984 -1989 (Table 6 ).
Discussion
An extended radical gastrectomy (R3) involving Group 1, 2 and 3 lymph node dissections has been widely accepted as the procedure of first choice for the treat ment of AGC. Beyond this, the para aortic lymph nodes (No. 16) are classified as Group 4 (n4) nodes, according to the Japanese Research Society for Gastric Cancer (1981). The No. 16 group includes the distant lymph nodes and are in the same group as Virchow's node from the stomach.
They are considered to be one of the non-curable factors for gastric cancer surgery.
However, recent studies of lymph flows from the stomach and from the perigastric nodes to No.16, using either black ink CH 44 (Takahashi et al. 1987; Matsuo, 1991) or 5-bromode oxyuridine monoclonal antibodies (Yamada et al. 1990 ) have found a direct lymph flow from No. 7 (lymph nodes along the left gastric artery) and No. 9 (lymph nodes around the celiac artery) -both be ing Group 2 lymph nodes-to No. 16 which therefore suggests that No. 16 is a Group 3 lymph node. Moreover, in cases of up-per gastric cancers, they also found a direct lymph flow from No. 1 and No. 2 (right and left cardial lymph nodes) of Group 1 to No. 16 along the left sub phrenic artery.
Lymph flow from the gastric cardia to No. 16 through the left subphrenic artery was found in 27% (12/45) of cases using the VX2 cardia cancer model in rabbits (Matsuo, 1991) .
Lymph flow from No. 1 and No. 2 of the Group 1 nodes to No. 16 has also been reported clinically in cases of advanced upper gastric cancer by Kitamura et al. (1989) and by Sasaki et al. (1989) .
Positive No. 16 metastasis from AGC has been reported to have occurred in 29.4% of cases by Takahashi et al. (1987 ), in 27.1% by Sasaki et al. (1989 , in 18% by Yonemura et al. (1991) and in 24% of cases in the present study. The inci dence of positive No. 16 metastasis in patients with serosal exposure was sig nificantly higher than in those without serosal invasion (Hashimoto et al. 1990 ). Upper gastric cancer is generally accepted as having the highest rate of No. 16 (+) when compared with middle and lower gastric cancers. Yonemura et al. (1991) reported that No. 16 of the inter-aorticovenous and left latero-aortic nodes lying above and below the renal vein must be completely removed.
A total of 37 patients have been de scribed in the Japanese literature to have had No. 16 (+) and survived for more than 5 years following R3 gastrectomy + No. 16 dissection.
In general, these patients had only 1 or 2 positive No. 16 nodes. Sasaki et al. (1989) has reported that the 5 year-survival rate was 34% after R3 + No. 16 dissection and 19% after R3 without No. 16 dissection. In 25 cases of Hi, P i that underwent R3 + No. 16 dis section, the 3 year-survival rate was only 4.9% and all died within 4 years. In the present study, R3 + No. 16 dissection did not increase the operative mortality and led to a much better prognosis than R3 gastrectomy.
However, the incidence of postoperative cylif orm ascites from the intra-abdominal drain was higher after R3+No. 16 dissection than after R3. More over, for R3 + No. 16 The standard indication of R3 + No. 16 dissection is for low risk patients less than 70 years old, and for Ho (no liver metastasis), Po (no peritoneal metastasis) and S2-3 AGC cases. There were several cases of Ho, Po, se, n1 (+), n2 (+), n3 (-), n4 (+), as shown in Table 3 
